India Telmisartan Market to grow at a steady rate During the Forecast Period
Growing prevalence of hypertension
is expected to drive the growth of India Telmisartan market.
According
to TechSci Research report, “India Telmisartan Market By Indication
(Hypertension, Cardiac Arrest, Stroke, Others), By Composition (Single,
Combinational), By Form (Tablet, Capsule, Injection, Others), By Route of
Administration (Oral v/s Intravenous), By Source (In-house v/s Contract
Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By
End User (Adult v/s Paediatric), By Company, By Region, Forecast &
Opportunities, FY2026”, the India telmisartan market
is expected to grow at a steady rate during the forecast period for the
treatment of essential hypertension. In addition to this, rising demand for
developing antihypertensive drugs is expected to fuel the market growth through
FY2026. However, side-effects associated with drug consumption such as upper
respiratory tract infections, diarrhea, back pain, kidney problems, low blood
pressure, and angioedema can restrict the market growth over the next few
years. Moreover, in certain cases use of this drug in pregnancy may harm the
baby. This can further reduce the usage and application of the drug thereby
hindering the market growth during the forecast period.
Browse XX market data Tables and XX
Figures spread through XXX
Pages and an in-depth TOC on" India Telmisartan Market "
https://www.techsciresearch.com/report/india-telmisartan-market/5150.html
The India telmisartan market is segmented based on indication,
composition, form, route of administration, source, distribution channel, end
user, company, and region. Based on indication, the market can be fragmented
into hypertension, cardiac arrest, stroke, others. The hypertension segment is
expected to dominate the market in the forthcoming years on account of rising prevalence
of high blood pressure among the population. Based on source, the market can be
categorized into in-house v/s contract manufacturing organizations. The in-house
segment dominated the market until 2017 as most of the leading companies focus
on in house production. Contract manufacturing organizations segment is
expected to witness significant growth in the market as it saves cost and
maximize profits. Besides, high growth in number of contract manufacturers is
further contributing to its fast growing CAGR. In terms of form, the market is
split into tablet, capsule, injection, others. Among them, the capsule segment
is anticipated to dominate the market in the next 5 years which is attributable
to the fact that they are easy to use and readily available. Also, the tablet
segment is expected to register high growth during then forecast years on
account of their properties such as high stability of tablets and longer shelf
life.
Astellas Pharma India Pvt. Ltd., Boehringer
Ingelheim India Pvt. Ltd., Novartis India Ltd., Venus Remedies Ltd., Candomed
Pharmaceuticals India Pvt. Ltd, Torrent Pharmaceuticals Ltd., Cipla Limited
(Exelan Pharmaceuticals), Lupin Laboratories Ltd., Mylan Laboratories Ltd., Glenmark
Pharmaceuticals Ltd., Astellas Pharma India Pvt. Ltd. and others are some of the leading players operating
in India telmisartan market. Companies operating in the market are using Go-To-Market
strategies such as product launches, mergers, and collaborations to boost their
share and increase their geographic reach. For instance, In 2017, Zydus Cadila
which is one of the leading pharmaceutical company in the market received
permission to sell its version of temisartan and hydrocholothiazide tablets and
the drug was brought into the market in three different dosages, which
contributed in strengthening their market share.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5150
Customers can also
request for 10% free customization on this report.
“India Telmisartan market is expected to
witness growth during the forecast period as it is used to treat patients with high
blood pressure and thereby aids to prevent strokes, heart attacks, and other related
conditions in an individual. Telmisartan medication is also very effective in
treating diabetic kidney disease. This is further expected to create lucrative
opportunities for the market growth of India Telmisartan market over the next
five years.” said Mr. Karan Chechi, Research Director with
TechSci Research, a research based India management consulting firm.
“India Telmisartan Market By Indication
(Hypertension, Cardiac Arrest, Stroke, Others), By Composition (Single,
Combinational), By Form (Tablet, Capsule, Injection, Others), By Route of
Administration (Oral v/s Intravenous), By Source (In-house v/s Contract
Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By
End User (Adult v/s Paediatric), By Company, By Region, Forecast &
Opportunities, FY2026”, has
evaluated the future growth potential of India telmisartan market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in India telmisartan market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]